SG
ARNA

Societe Generale’s Arena Pharmaceuticals Inc ARNA Stock Holding History

Societe Generale’s Portfolio ARNA Stock Details ARNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$80K Buy
+4,704
New +$84.1K ﹤0.01% 2419

Other funds holding ARNA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Societe Generale's ARNA Position: Q2 2016 in Review

Societe Generale opened a new position in Arena Pharmaceuticals Inc (ARNA) in Q2 2016: 4,704 shares worth $80K. The stake represents ﹤0.01% of the portfolio and ranks #2419 among its holdings.

119 funds tracked by Wall St. Rank hold ARNA as of Q2 2016.

  • Societe Generale held 4,704 shares of Arena Pharmaceuticals Inc worth $80K as of Q2 2016.
  • Arena Pharmaceuticals Inc was a new Societe Generale position in Q2 2016.
  • Arena Pharmaceuticals Inc made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #2419 holding.
  • 119 funds tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.